Alyeska Investment Group, L.P. Biomarin Pharmaceutical Inc Transaction History

Alyeska Investment Group, L.P.

$18 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $11.3 Million - $14 Million	151,865 Added 60.75%	401,865 $33.1 Million
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $11.3 Million - $13.4 Million	-134,944 Reduced 35.06%	250,000 $21.8 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $14.9 Million - $19.2 Million	194,944 Added 102.6%	384,944 $37.1 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $12.9 Million - $14.9 Million	-148,857 Reduced 43.93%	190,000 $16.5 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $14.2 Million - $19 Million	-161,615 Reduced 32.29%	338,857 $33 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $6.04 Million - $8.1 Million	-74,595 Reduced 12.97%	500,472 $51.8 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $35.8 Million - $42.2 Million	435,539 Added 312.15%	575,067 $48.7 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $6.26 Million - $7.61 Million	87,640 Added 168.9%	139,528 $11.6 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $12.7 Million - $15.8 Million	-175,515 Reduced 77.18%	51,888 $4.55 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $7.61 Million - $13.9 Million	105,945 Added 87.23%	227,403 $17.3 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $12.5 Million - $19.5 Million	-157,164 Reduced 56.41%	121,458 $15 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $3.46 Million - $4.7 Million	-48,490 Reduced 14.82%	278,622 $23.5 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $7.88 Million - $10.6 Million	122,633 Added 59.97%	327,112 $27.7 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $1.29 Million - $1.63 Million	-19,101 Reduced 8.54%	204,479 $13.8 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $17.7 Million - $20.7 Million	220,610 Added 7427.95%	223,580 $0
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $52.1 Million - $58.6 Million	-554,731 Reduced 99.47%	2,970 $288,000
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $251,213 - $327,294	3,305 Added 0.6%	557,701 $52.5 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $16.9 Million - $20.1 Million	-217,319 Reduced 28.16%	554,396 $44.9 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $4.57 Million - $5.38 Million	56,534 Added 7.9%	771,715 $68.8 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $57.6 Million - $67.9 Million	715,181	715,181 $66.6 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.52 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.26 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$926 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$699 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.

Account